Is NK Cell Therapy Covered by Insurance in Japan? What to Ask in Osaka

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

When people first read about NK cell therapy, one of the earliest practical questions is about money: will national health insurance or my overseas insurance help pay for it? This article explains, in general terms, how NK cell therapy is positioned within the Japanese system and which questions are worth bringing to a consultation at Grand Green Osaka Umekita Clinic or any other clinic you are considering.

The short answer: it is a self-pay treatment

NK cell therapy, in which a patient’s own natural killer cells are activated and expanded outside the body and then returned by IV infusion, is provided in Japan as a self-pay treatment. In Japanese this is called jiyu shinryo, meaning medical care that is not covered by the public health insurance system. In practice, this means the full cost of the consultation, tests, cell preparation and infusions is paid by the patient rather than shared with the national insurance scheme.

Being outside public insurance does not by itself say anything about whether a treatment is good or poor. It simply reflects how the treatment is classified. Standard cancer care such as surgery, chemotherapy and radiation therapy is typically what insurance covers, and NK cell therapy is generally considered as an additional option that a patient may discuss with a doctor, not as a replacement for that standard care.

Why regenerative medicine in Japan is regulated separately

Cell-based treatments offered as self-pay medicine in Japan fall under the Act on the Safety of Regenerative Medicine. Under this law, a clinic must submit a treatment plan that is reviewed by a certified committee and then accepted by the Ministry of Health, Labour and Welfare before it can offer the therapy. Cells are processed at a facility that is licensed or notified under the same framework.

For patients, this framework is useful mainly as a point of reference. It is reasonable to ask a clinic which plan covers the therapy you are being offered, where the cells are prepared, and how adverse events are reported and handled. A clear answer to these questions is a sign of transparency, although it does not remove the need for your own careful judgment.

What international patients should know about overseas insurance

Many international patients wonder whether a private or employer-provided insurance plan from their home country might reimburse treatment received in Japan. Policies differ widely, and many exclude treatments that are considered investigational or that are not approved in the insurer’s own country. Because of this, it is wise to contact your insurer before traveling and ask directly whether cell-based immunotherapy delivered abroad could be eligible for any reimbursement.

It can also help to ask the clinic what documents it can provide, such as an itemized statement, a medical certificate or a treatment summary in English. Whether any of these will be accepted is a decision for your insurer, and it should not be assumed in advance.

Questions to ask about cost before you commit

Because the fees for self-pay medicine are set by each clinic, the amount and structure can differ from one provider to another. Rather than relying on a single headline number, it is more useful to understand what is included. Consider asking the following:

• What exactly does the quoted fee include: consultation, blood tests, cell culture, each infusion and follow-up?
• How many infusions are usually planned in one course, and how is the overall duration decided?
• Are there additional charges for pre-treatment testing, interpretation services or medical documents?
• What happens to the fee if the treatment plan changes or has to stop for medical reasons?
• What are the accepted payment methods for patients visiting from abroad?

The clinic’s own fee page and the doctor’s explanation during the consultation are the authoritative sources for these details. Please do not rely on figures from third-party websites, since they may be outdated or may describe a different clinic.

Balancing cost with expectations, risks and limits

Cost should be considered together with what the therapy can and cannot be expected to do. Research on NK cells and adoptive cell transfer is ongoing, and results in published studies vary by cancer type, cell source, dose and patient condition. No individual outcome can be promised, and NK cell therapy is not a substitute for standard treatment.

Side effects are also part of the picture. Because the therapy uses a patient’s own cells, serious reactions have rarely been reported, but temporary fever or fatigue may occur. Whether the therapy is appropriate for you depends on your diagnosis, current treatments, overall health and goals, which is why a physician’s examination comes first. If you are receiving surgery, chemotherapy or radiation at another institution, it is sensible to keep that team informed and to ask whether coordination is possible.

Preparing for a consultation in Osaka

Grand Green Osaka Umekita Clinic is located in the Umeda area of Osaka and provides information pages in multiple languages for overseas patients. Before your first visit, it can be helpful to gather your diagnosis summary, recent imaging or blood test results, a list of current medications and a short note of your questions about cost, schedule and risks. Having these ready makes the conversation with the doctor more productive, particularly when time during a trip is limited.

Please remember that eligibility, fees, number of infusions, risks and side effects are all confirmed during the physician’s consultation. Reading the clinic’s NK cell therapy page, its fee information and its FAQ beforehand can help you prepare better questions, and you can contact the clinic through its multilingual channels if something is unclear. Taking the time to compare information and to speak with your own doctor at home is a reasonable step before deciding.

1. 1Self-pay treatmentNot covered by public insurance
2. 2Check the legal planRegenerative medicine framework
3. 3Ask your insurerOverseas coverage may differ
4. 4Confirm what fees include
5. 5Understand risks and limits

This figure is a conceptual summary of the article content

References

• PubMed: CAR-NK cells: A promising cellular immunotherapy for cancer. (2020)
• PubMed: Immunotherapy. Neuroblastoma as a model. (1991)
• PubMed: Prospects for gene therapy and lymphokine therapy for metastatic melanoma. (1992)
• PubMed: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. (2023)
• PubMed: The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes. (2021)
• MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.